Inhibition of TGF-β3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies

Isabella Caniggia, … , Martin Post, Stephen J. Lye


Preeclampsia, the major cause of maternal morbidity and mortality in developed countries, is associated with abnormalities of placenta function due to shallow invasion of the maternal decidua by trophoblasts. Data suggest that TGF-β may play a role in inhibiting trophoblast outgrowth or invasion, or both. We report that placental TGF-β3 expression is high in early pregnancy but falls at around 9 weeks’ gestation. This pattern is inversely correlated with trophoblast outgrowth and fibronectin synthesis, markers of early trophoblast differentiation toward an invasive phenotype. We demonstrate that TGF-β3 is overexpressed in preeclamptic placentae. In contrast to control placentae, explants from preeclamptic pregnancies fail to exhibit spontaneous invasion in vitro. Significantly, antisense-induced inhibition of TGF-β3 expression, and inhibition of TGF-β3 activity with antibodies, induces the formation of columns of trophoblast cells, which migrate out of the explant into the underlying Matrigel. To our knowledge, this is the first demonstration that the hypoinvasive placental phenotype characteristic of preeclampsia can be essentially normalized in vitro by biochemical manipulation. We speculate that a failure to downregulate expression of TGF-β3 at around 9 weeks’ gestation results in shallow trophoblast invasion and predisposes the pregnancy to preeclampsia.

Find the latest version:

http://jci.me/6380-pdf
Inhibition of TGF-β3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies

Isabella Caniggia,1–4 Sorina Grisaru-Gravnosky,2 Maciej Kuliszewsky,5 Martin Post,3–5 and Stephen J. Lye1–3

1Program in Fetal Health and Development, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 2Department of Obstetrics and Gynaecology, 3Department of Physiology, 4Department of Pediatrics, and 5Division of Neonatology Research, The Hospital for Sick Children, University of Toronto, Toronto, Ontario MSG 1X8, Canada

Address correspondence to: Isabella Caniggia, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario MSG1X5, Canada. Phone: (416) 586-4803; Fax: (416) 586-8745; E-mail: Caniggia@mshri.on.ca.

Preeclampsia, the major cause of maternal morbidity and mortality in developed countries, is associated with abnormalities of placenta function due to shallow invasion of the maternal decidua by trophoblasts. Data suggest that TGF-β may play a role in inhibiting trophoblast outgrowth or invasion, or both. We report that placental TGF-β3 expression is high in early pregnancy but falls at around 9 weeks’ gestation. This pattern is inversely correlated with trophoblast outgrowth and fibronectin synthesis, markers of early trophoblast differentiation toward an invasive phenotype. We demonstrate that TGF-β3 is overexpressed in preeclamptic placentae. In contrast to control placentae, explants from preeclamptic pregnancies fail to exhibit spontaneous invasion in vitro. Significantly, antisense-induced inhibition of TGF-β3 expression, and inhibition of TGF-β3 activity with antibodies, induces the formation of columns of trophoblast cells, which migrate out of the explant into the underlying Matrigel. To our knowledge, this is the first demonstration that the hypoinvasive placental phenotype characteristic of preeclampsia can be essentially normalized in vitro by biochemical manipulation. We speculate that a failure to downregulate expression of TGF-β3 at around 9 weeks’ gestation results in shallow trophoblast invasion and predisposes the pregnancy to preeclampsia.

inhibits the differentiation of trophoblasts toward an invasive phenotype and suppresses trophoblast endocrine differentiation (26). We have recently reported that activin, a member of the TGF-β superfamily, stimulates trophoblast differentiation toward an invasive phenotype (including trophoblast outgrowth and proliferation from villous tips, integrin switching, fibronectin synthesis, and induction of gelatinase activity) in first-trimester placental explants (27). Surprisingly, antisense-induced downregulation of the TGF-β receptor endoglin also induces trophoblast differentiation in this system (28).

In the present study, we have investigated the role of the 3 mammalian isoforms of TGF-β in normal pregnancies and in pregnancies complicated by preeclampsia. We report that TGF-β3, but not TGF-β1 or TGF-β2, inhibits trophoblast differentiation toward an invasive phenotype in first-trimester human placental explants. Preeclamptic placenta overexpress TGF-β3 and exhibit a hypoinvasive phenotype in vitro. Differentiation toward the invasive phenotype can be restored in these explants by antibody and antisense disruption of endogenous TGF-β3 activity and synthesis, respectively.

Methods

Human chorionic villous explant culture. Villous explant cultures were established from first-trimester human placentae (5–13 weeks’ gestation) obtained from elective terminations of pregnancies by dilatation and curettage. Villous explant cultures were also prepared from preeclamptic and age-matched control placentae (30 and 32 weeks’ gestation) collected from deliveries at Mount Sinai Hospital. The preeclamptic group was selected to represent classic preeclampsia according to both clinical and pathological criteria (29). The age-matched control groups were primiparous but did not show clinical and pathological signs of preeclampsia or other placental disease. Villous explant cultures were established as described previously (28, 30). Briefly, placental tissue was placed in ice-cold PBS and processed within 2 hours of collection. The tissue was aseptically dissected to remove decidual tissue and fetal membranes. Small fragments of placental villi (15–20 mg wet weight) were teased apart and placed on Millicell-CM culture dish inserts (Millipore Corp., Bedford, Massachusetts, USA) precoated with 0.2 mL of undiluted Matrigel (Collaborative Biomedical Products, Bedford, Massachusetts, USA), and placed in a 24-well culture dish. Explants were cultured in serum-free DMEM/F12 (GIBCO BRL, Grand Island, New York, USA) supplemented with 100 μg/mL streptomycin, 100 U/mL penicillin, and 0.25 μg/mL ascorbic acid (pH 7.4) overnight at 37°C in 5% CO2 in air to allow attachment. In all
experiments, a single placenta was used, and for each treatment, explant cultures were set up in triplicate. Morphological integrity and viability of villous explants and their EVT differentiation were monitored for up to 6 days as reported previously (30). EVT cell outgrowth from the distal end of the villous tips and their migration into the surrounding Matrigel were consistently monitored and quantitated as described previously (28).

**Antisense oligonucleotides and their effects on trophoblast differentiation.** Phosphorothioate oligonucleotides were synthesized on a DNA synthesizer and purified by capillary electrophoresis. Oligonucleotides of 16 bp targeted against sequences adjacent to the AUG initiation codon of different human TGF-β isoforms mRNA were synthesized (31). Previous studies have demonstrated that antisense oligonucleotides, targeted to sequences adjacent to initiation codons, are most efficient in inhibiting translation (32). Furthermore, 16-mer oligonucleotides are short enough to be taken up efficiently and provide sufficient specificity for hybridization to the corresponding target mRNA (32). The sequences of the antisense and sense TGF-β1 oligonucleotides were TGF-β1; 5'-CCCCGAGGGCCGCACTG-3' and 5'-CATGCGGCTTGGGG-3', respectively; TGF-β2; 5'-CACACAGTAGTGCATG-3' and 5'-CATGCACTACTGGTG-3', TGF-β3; 5'-CCTTGTCAAGTCATGCAT-3' and 5'-GATGCACATTGCAAAGG-3'. Oligonucleotides were dissolved in water, and their concentration was estimated by optical density at OD_{260}. Villous explants, prepared from placentae of 5–13 weeks' gestation and from preeclamptic and age-matched control placentae of 29–32 weeks, were incubated overnight in DMEM/F12 alone. Explant cultures were then incubated in DMEM/F12 alone or medium containing antisense or sense oligonucleotides (10 μM). Culture media in the presence or absence of treatments were routinely changed every 48 hours. Experiments were carried out in triplicate and repeated at least 3 times.

**TGF-β antibodies and their effect on trophoblast differentiation.** Villous explants, prepared from placentae of 5–13 weeks' gestation and from preeclamptic and age-matched control placentae of 29–32 weeks, were incubated overnight in DMEM/F12 alone. Explant cultures were then incubated in DMEM/F12 alone or medium containing antibodies to TGF-β1, TGF-β2, TGF-β3, or control IgG (10 μg/ml). Culture media in the presence or absence of treatments were routinely changed every 48 hours. Experiments were carried out in triplicate and repeated at least 3 times.

**RT-PCR and Southern blot analysis.** Total RNA was extracted from the placenta, reverse transcribed, and amplified by 15 cycles of PCR using TGF-β-specific primers. RT-PCR products were analyzed by Southern blotting using 32P-labeled TGF-β1, TGF-β2, TGF-β3, or control IgG (10 μg/ml). Culture media in the presence or absence of treatments were routinely changed every 48 hours. Experiments were carried out in triplicate and repeated at least 3 times.

**Antisense and sense digoxigenin-labeled TGF-β1 riboprobes** (33) were generated as described in the RNA labeling and detection kits (nonradioactive) from Boehringer Mannheim (Laval, Quebec, Canada). In situ hybridization to placental tissue from the first trimester (5–13 weeks' gestation) and from normal pregnancies and pregnancies complicated by preeclampsia at delivery (26–34 weeks' gestation) was performed according to Braissant and Wahl (34).
Figure 3
Antisense oligonucleotides and antibody to TGF-β1, but not to TGF-β2 or TGF-β3, induce trophoblast outgrowth and migration in vilous explant cultures. (a) Vilous explants from 5–8 weeks’ gestation were maintained in culture for 5 days in the presence of 10 μM antisense oligonucleotides to TGF-β1 (AS-β1), TGF-β2 (AS-β2), and TGF-β3 (AS-β3). Control experiments were run in parallel using explants from the same placenta cultured in either medium alone or medium containing sense oligonucleotides. (b) Vilous explants from 5–8 weeks’ gestation were maintained in culture for 5 days in the presence of 10 μg/mL of neutralizing antibody to TGF-β1 (Ab-β1), TGF-β2 (Ab-β2), and TGF-β3 (Ab-β3). Control experiments were run in parallel using explants from the same placenta cultured in either medium alone or in medium containing IgG control. Note that both antisense TGF-β1 (AS-β1) and antibody TGF-β1 (Ab-β1) treatments dramatically increase budding and outgrowth of EVT from the distal end of the vilous tips when compared with control vilous explants or explants exposed to TGF-β1 and TGF-β3 antisense oligonucleotides and antibodies. ×50.
Results
Developmental regulation of TGF-β3 expression in the first trimester. Low-cycle RT-PCR followed by Southern blot analysis and immunohistochemistry was used to define the pattern of expression of TGF-β isoforms in the human placenta during the first trimester of pregnancy. All 3 isoforms of TGF-β were expressed during the first trimester (Figure 1a). However, although transcripts corresponding to TGF-β1 and TGF-β2 were uniformly expressed throughout this period, the expression of TGF-β3 exhibited a striking pattern of developmental regulation. TGF-β3 mRNA levels were relatively low at 5–6 weeks, increased markedly between 7 and 8 weeks, and then fell precipitously at 9 weeks. To determine the spatial pattern of TGF-β3 mRNA expression, we performed in situ hybridization to placental sections from 5–10 weeks’ gestation using a TGF-β3 riboprobe. Figure 1b shows a representative experiment demonstrating that high levels of TGF-β3 mRNA were detected in sections of 7-week placenta in syncytiotrophoblast, cytotrophoblast, and stromal cells. By 9–10 weeks’ gestation, the mRNA expression of TGF-β3 in all cell layers declined. This spatial and temporal expression pattern for TGF-β3 was confirmed at the protein level by immunohistochemistry (Figure 1c). Villous trophoblasts from a placenta of 8 weeks stained positively for TGF-β3. In contrast, TGF-β1 immunoreactivity was noticeably low or absent in villous trophoblast cells of 12-week placental tissue. No reactivity was observed in placental sections stained with anti-sera preabsorbed with peptide.

Temporal and spatial differentiation of first-trimester villous trophoblasts toward an invasive phenotype in vitro. Because TGF-β regulates interactions of cells with the extracellular matrix molecules, as well as interactions between cells, it was particularly relevant to study its effects on trophoblast differentiation toward an invasive phenotype in a system in which the placental villous tissue architecture is maintained. Placental villous explants in culture preserve the topology of intact villi and mimic closely the formation of anchoring villi occurring in vivo during the first trimester of pregnancy (27, 28, 30). We first investigated the temporal differentiation of first-trimester villous trophoblasts toward an invasive phenotype using the villous explant system. Explants from placentae of 5–7, 8, or 9–13 weeks’ gestation were cultured on a Matrigel base for 6 days, and their differentiation was assessed using morphological and biochemical markers of early trophoblast differentiation, namely, outgrowth of EVT cells (EVT outgrowth) from the explant and fibronectin synthesis, respectively. Explants at 9–13 weeks’ gestation showed significantly greater EVT outgrowth and fibronectin synthesis compared with those at 5–8 weeks (Figure 2, a and b).

Inhibition of TGF-β3 expression and activity initiates trophoblast differentiation toward an invasive phenotype. To determine the functional significance of the TGF-β expression patterns, we monitored trophoblast differentiation in response to both TGF-β antibody (10 µg/mL) and antisense oligonucleotide–induced inhibition of TGF-β3 expression in explants at 5–8 weeks’ gestation. EVT outgrowth was not significantly increased after exposure to antisense oligonucleotides or antibodies to TGF-β1 or TGF-β2 (Figure 3, a and b). In contrast, explants exposed to either antisense TGF-β3 oligonucleotide or TGF-β3 antibody displayed prominent EVT outgrowth from the distal end of the villous tip and an increased number of cells migrating into the surrounding matrix (Figure 3, a and b; see Figure 5a). Characterization of the EVT in the villous outgrowths of antisense TGF-β3 oligonucleotide–treated explants with various markers was performed as described earlier (27, 28). During the differentiation pathway, EVT start to express fibronectin. We thus investigated the effect of antisense oligonucleotide to the different TGF-
Figure 5

The antisense TGF-β3 stimulatory effect on trophoblast migration and on fibronectin production is specific. Explants of 5–8 weeks’ gestation were treated for 5 days with 10 μM antisense oligonucleotides to TGF-β3 (AS-β3), plus 10 ng/mL recombinant TGF-β1 (AS-β1+β3), TGF-β1 (AS-β1), or TGF-β3 (AS-β3). Control experiments were run in parallel using sense TGF-β3 (S-β3) or medium alone (C). (a) Shown is a representative experiment demonstrating that addition of recombinant TGF-β3 to antisense TGF-β3−treated explants (AS-β3+β3) abolishes the antisense stimulatory effect on trophoblast budding and outgrowth (arrows). ×25. (b) Similar reversal of AS-β3 stimulation of fibronectin synthesis by exogenous TGF-β3. A representative analysis of triplicate samples from a single experiment is shown. The position of the marker with M₀ = 200,000 is indicated. (c) Radiolabeled bands were quantified with the use of a PhosphorImager. Shown are the changes in fibronectin estimated after normalization to control cultures. Antisense TGF-β3 treatment (AS-β3) significantly increased the production of fibronectin when compared with both medium alone (C) or sense oligonucleotide (S-β3). Addition of exogenous TGF-β3 (AS-β3+β3), but not TGF-β1 (AS-β1+β3) or TGF-β3 (AS-β3+β3), to the antisense-treated explants abolished the antisense stimulatory effect on fibronectin production. (d) mRNA expression of TGF-β3 in explants treated with antisense (AS-β3) or control sense (S-β3) oligonucleotides was measured by low-cycle RT-PCR followed by Southern blot analysis using specific probes for TGF-β1 and the control housekeeping gene β-actin. (e) The antisense TGF-β3 stimulatory effect on fibronectin production is lost by 10 weeks’ gestation. Explants of 6 and 10 weeks’ gestation were treated with 10 μM antisense (AS-β3) or control sense (S-β3) oligonucleotides to TGF-β3. Newly synthesized fibronectin was isolated from the medium as already described here. Representative analysis of triplicate samples from a single experiment is shown. (f) Antisense TGF-β3 treatment of villous explants (AS-β3) inhibits TGF-β3 mRNA but not TGF-β1 or TGF-β2 mRNA.

β isoforms on fibronectin synthesis by villous explants of 5–8 weeks’ gestation. Explants were metabolically labeled on day 5 with [35S]methionine, and newly synthesized fibronectin released into the medium over a period of 18 hours was measured. Antisense oligonucleotide to TGF-β3, but not TGF-β1 or TGF-β2, significantly increased the production of fibronectin when compared with that observed in control cultures treated with sense oligonucleotide or medium alone (Figure 4). Thus the morphological response after antisense TGF-β3 treatment is associated with a significant increase in fibronectin synthesis. The specificity of the antisense TGF-β3 response was demonstrated by reversal of both morphological and biochemical indices when antisense-treated explants were cultured in the presence of TGF-β3 but not TGF-β1 or TGF-β2 (Figure 5, a–c). Further experiments demonstrated that treatment of villous explants with antisense oligonucleotide to TGF-β3 abolished TGF-β3 mRNA expression (Figure 5, d and f), but not that of TGF-β1 or TGF-β2 (Figure 5f), corroborating the specificity of the antisense TGF-β3 effect. TGF-β3 is not expressed in villous trophoblasts at ≥9 weeks (Figure 1). Indeed, antisense oligonucleotide to TGF-β3 had no effect on fibronectin synthesis in villous explants of 10 weeks’ gestation (Figure 5e).

Preeclampsia is associated with a failure to downregulate trophoblast expression of TGF-β3. We next characterized the expression of the 3 TGF-β isoforms in villous placental tissue from patients across a range of gestational ages who were diagnosed as severe preeclamptics. TGF-β expression in these samples was compared with that in an age-matched control group of nonpreeclamptic patients by low-cycle RT-PCR followed by Southern blotting and immunohistochemistry. We detected mRNA
encoding TGF-β3, but not TGF-β1 or TGF-β2, at higher levels in preeclamptic placentae than in controls (Figure 6a). We also observed elevated levels of α5-integrin and fibronectin mRNA (Figure 6a) and absence of α1-integrin mRNA (data not shown) in preeclamptic placentae, consistent with previous data (12) suggesting that trophoblast differentiation is arrested at an early stage along the invasive pathway in these placentae. The aberrant expression of TGF-β3 in preeclamptic placentae was further confirmed by histochemical analysis. In situ hybridization and immunohistochemistry showed high TGF-β3 expression in the syncytiotrophoblast cells in villous tissues from preeclamptic patients, whereas little or no signal was present in the age-matched controls (Figures 6b and 7). In contrast, immunohistochemical analysis demonstrated no differences for TGF-β1 and TGF-β2 expression between preeclamptic and age-matched control placentae (Figure 7).

Inhibition of TGF-β3 expression and activity in preeclamptic placentae restores invasive capability of trophoblasts. To determine whether there was functional significance associated with overexpression of TGF-β3 in preeclamptic placentae, we analyzed trophoblast differentiation in explants from control and preeclamptic patients. When cultured on Matrigel, explants from a nonpreeclamptic patient showed formation of EVT columns that spontaneously invaded into the surrounding Matrigel (Figure 8a, panels 1 and 5). In contrast, explants from preeclamptic placentae failed to exhibit EVT outgrowth or invasion (Figure 8a, panels 2 and 6). These data are consistent with the view that preeclampsia is associated with reduced invasive capability of trophoblasts. To determine whether this reduced invasive capability was due to TGF-β3 over-expression, we monitored trophoblast differentiation in villous explants from preeclamptic patients cultured in the presence of antibody and antisense oligonucleotide to TGF-β3. In contrast to untreated or sense-treated controls, treatment of explants from preeclamptic patients with antisense TGF-β3 restored the invasive capability, as demonstrated by the formation of EVT columns migrating through the Matrigel (Figure 8a, panel 5). Similar stimulatory effect on EVT column formation was observed with an antibody to TGF-β3 (Figure 8a, panel 3). The specificity of the antisense TGF-β3 response was demonstrated by reversal of this effect when antisense-treated explants were cultured in the presence of 10 ng/mL TGF-β3 (Figure 8a, panel 4). Further experiments demonstrated that treatment of explants from preeclamptic pregnancies with antisense oligonucleotide or antibodies to TGF-β1 or TGF-β2 did not show any effect on EVT column formation (data not shown), indicating that only the inhibition of the TGF-β3 isoform induces the invasive phenotype. The invasive nature of this antisense-induced phenotype was confirmed by the finding that explants treated with antisense TGF-β3 acquired the expression of gelatinase B/MMP-9, an enzyme that is normally only expressed in trophoblast cells that are highly invasive (Figure 8b). Treatment of
centae ranging from 27 to 34 weeks’ gestation.

Antisense and antibody inhibition of TGF-β3 in human villous explants at 6–8 weeks of pregnancy induced a premature switch to the differentiative/invasive phenotype normally seen at 9–13 weeks (when endogenous expression of TGF-β3 is reduced). The data strongly suggest that TGF-β3 acts as an inhibitor of trophoblast differentiation toward an invasive phenotype. This conclusion is consistent with reports of the anti-invasive actions of other TGF-β isoforms (primarily TGF-β1) on other cell/tissue systems including colon carcinoma and thyroid cells (22–24). There have been conflicting data as to the actions of TGF-β1 on trophoblast invasion. Some investigators have reported inhibition of the invasive capability of isolated first-trimester trophoblasts, possibly through an induction of TIMP expression or reduced urokinase plasminogen activator (uPA) activity (25). In other studies, TGF-β1 was not able to inhibit invasion of isolated first-trimester trophoblasts (18). It is likely that the isolation of different trophoblast subpopulations (due to different preparation methodologies or pooling of late first-trimester placentae) may underlie these contradictory reports. Cell-matrix and cell-cell interactions are known to be critical modulators of TGF-β action, and the maintenance of such interactions in the placental explants may be important in revealing the anti-invasive actions of TGF-β3.

Expression of TGF-β3 in placental trophoblasts peaks at 6–8 weeks’ gestation and then falls precipitously around 9 weeks, precisely at the time of maximal trophoblast invasion in vivo (4). This downregulation of TGF-β3 expression is temporally associated with earlier reports of major changes in the expression of markers of trophoblast differentiation toward an invasive phenotype in anchoring villi, including switching of integrin isoforms (36–38), synthesis of matrix ligands for these integrins (39, 40), and upregulation of gelatinase A (MMP-2) (21). Previous studies have suggested that the trophoblasts from preeclamptic placentae exhibit a relatively immature phenotype. Thus, preeclamptic placentae fail to complete integrin switching (i.e., the trophoblasts remain positive for α5 and fail to express β3) (12); do not acquire an endovascular adhesion phenotype (41); demonstrate an excess of proliferative immature intermediate trophoblasts (11); and also maintain elevated plasma levels of fibronectin (40, 42) (a marker of the initial phase of trophoblast differentiation). Our observation of increased fibronectin and α5 mRNA levels (with no α1 expression) in preeclamptic versus age-matched control placentae supports these findings. Moreover, we now report that TGF-β3, expressed in first-trimester trophoblasts before their differentiation along the invasive pathway, is also overexpressed in preeclamptic placenta.

Figure 7
Immunoperoxidase staining of TGF-β1, TGF-β2, and TGF-β3 was performed in placental sections from normal pregnancies and pregnancies complicated by preeclampsia. Sections of both normal and preeclamptic placental tissue of 29 weeks’ gestation show low/absent TGF-β3 immunoreactivity in cells of the chorionic villi. Sections of both normal and preeclamptic placental tissue of 32 weeks’ gestation show positive TGF-β3 immunoreactivity in the syncytiotrophoblast (ST, arrow) and in stromal cells (S) of the chorionic villi. Control experiments were performed using antisera preabsorbed with an excess of peptide. ×100. Immunostaining for TGF-β1, TGF-β2, and TGF-β3 was repeated in 5 different preeclamptic and age-matched control placentae ranging from 27 to 34 weeks’ gestation.

Discussion
Here we show that TGF-β3 is a regulator of human trophoblast differentiation toward an invasive phenotype. A failure to downregulate expression of this cytokine is associated with, and may contribute to, the pathogenesis of preeclampsia in humans. The conclusion that TGF-β3 is a major factor in the pathogenesis of preeclampsia is based on 3 observations: first, the distinct temporal and spatial patterns of TGF-β3 expression in normal and preeclamptic pregnancies; second, the demonstration that the invasive phenotype of trophoblasts can be prematurely triggered in first-trimester placentae by downregulation of TGF-β3; and third, the observation that the normal invasive phenotype was restored in preeclamptic placentae by both antibody and antisense inhibition of trophoblast TGF-β3 expression.
There have been several descriptive reports of various markers associated with preeclampsia, including TNF-α, human leukocyte antigen-G, VEGF, M-CSF, uPA, and IGFs (43–48). The precise role, if any, of these proteins in preeclampsia is unclear. The data presented here demonstrate not only that abnormalities in TGF-β3 expression are associated with preeclampsia but also that inhibition of TGF-β3 with antibody and antisense oligonucleotides restores the invasive capability of preeclamptic trophoblasts. Thus, we found morphological (formation of invading trophoblast columns) and biochemical (induction of MMP-9, a marker of trophoblast invasion; ref. 21) evidence of induction of an invasive phenotype following antisense TGF-β3 treatment. Our data are consistent with a model of normal placentation in which downregulation of TGF-β3 expression in trophoblasts around 9 weeks of pregnancy permits differentiation of trophoblasts to EVT that form the anchoring villi and from which derive the α1-integrin–positive EVT that can invade deep into the maternal uterus. This invasion contributes to the remodeling of the uterine spiral arteries and ultimately enables the establishment of increased vascular perfusion of the placenta. In placentae predisposed to preeclampsia, TGF-β3 expression remains abnormally elevated and trophoblasts remain in a relatively immature state of differentiation. As a direct consequence, trophoblast invasion into the uterus is limited and uteroplacental perfusion is reduced. This conclusion is consistent with the clinical manifestations of preeclampsia, including shallow trophoblast invasion into the uterus and abnormally high uteroplacental vascular resistance. Nevertheless, the aberrant expression of a large number of factors in preeclamptic pregnancies suggests that the pathogenesis of this disease is complex and likely involves many regulatory systems.

The data in this article suggest that the monitoring of TGF-β3 expression may be a useful diagnostic marker of preeclampsia. Equally important, these data suggest a novel target for therapeutic intervention to ameliorate or prevent this life-threatening condition.
Acknowledgments

We thank Lindsay McWherter for providing the placental samples. We also thank Alan Bernstein, John Kingdom, James Copeman, and Jay Cross for carefully reading the manuscript, and Knox Ritchie for the constant support. This work was supported by the Department of Obstetrics and Gynaecology, Medical Research Council of Canada (MRC) grant MT-14096 (to I. Caniggia), MRC Group Grant in Developmental and Fetal Health (to S.J. Lye), and MRC Group Grant in Lung Development (to M. Post).


